Isolated and purified strains of Chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

Patent metadata

Field	Value
Publication number	US-9442114-B2
Application number	US-201414335065-A
Country	US
Kind code	B2
Filing date	Jul 18, 2014
Priority date	Mar 15, 2006
Publication date	Sep 13, 2016
Grant date	Sep 13, 2016

Abstract

The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.

First claim

The invention claimed is:

1. A vector comprising a nucleotide sequence encoding a Chikungunya virus E2 protein and a heterologous nucleotide sequence regulating expression of the E2 protein, wherein the E2 protein comprises a threonine at amino acid position 489 of the Chikungunya virus E2 protein and a methionine at amino acid position 637 of the Chikungunya virus E2 protein.

2. The vector of claim 1 , further comprising a nucleotide sequence encoding a Chikungunya E1 protein and a heterologous nucleotide sequence regulating expression of the E1 protein, wherein the E1 protein comprises a valine at amino acid position 1078 of the Chikungunya virus E1 protein, a glutamic acid at position 1093 of the Chikungunya virus E1 protein and an alanine at position 1131 of the Chikungunya virus E1 protein.

3. The vector of claim 1 , further comprising a nucleotide sequence encoding a Chikungunya 6K protein and a heterologous nucleotide sequence regulating expression of the 6K protein, wherein the 6K protein comprises an isoleucine at amino acid position 756 of the Chikungunya virus 6K protein and a valine at position 802 of the Chikungunya virus 6K protein.

4. The vector of claim 1 , wherein the E2 protein further comprises a lysine at amino acid position 382, a methionine at amino acid position 399, a glutamic acid at amino acid position 404, a threonine at amino acid position 485, a methionine at amino acid position 506, a threonine at amino acid position 536, an asparagine at amino acid position 624, a threonine at amino acid position 669, a threonine at amino acid position 700, and an alanine at amino acid position 711 of the Chikungunya virus E2 protein.

5. The vector of claim 4 , wherein the vector encodes the amino acid sequence of SEQ ID NO:21.

6. The vector of claim 5 , wherein the vector is a viral vector.

7. The vector of claim 6 , wherein the vector is a recombinant lentiviral vector.

8. The vector of claim 5 , wherein the vector is plasmid.

9. The vector of claim 5 , wherein the vector comprises a synthetic soluble E2 gene that has been modified for optimal codon usage in mammalian cells.

10. A method for producing a Chikungunya virus E2 protein comprising introducing the vector of claim 5 into a host cell.

11. The vector of claim 1 , wherein the vector encodes the amino acid sequence of SEQ ID NO:27.

12. A method for producing a Chikungunya virus E2 protein comprising introducing the vector of claim 11 into a host cell.

13. The vector of claim 1 , wherein the vector is a viral vector.

14. The vector of claim 13 , wherein the vector is a recombinant lentiviral vector.

15. The vector of claim 1 , wherein the vector is plasmid.

16. The vector of claim 1 , wherein the vector comprises a synthetic soluble E2 gene that has been modified for optimal codon usage in mammalian cells.

17. A method for producing a Chikungunya virus E2 protein comprising introducing the vector of claim 1 into a host cell.

Assignees

• Pasteur Institut

Inventors

• Despres Philippe
• Brehin Anne-Claire
• Marechal Valerie
• Charneau Pierre
• Souque Philippe

Classifications

• A61P31/12

  Antivirals · CPC title

• C07K16/116

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• C12N2770/36122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• G01N2800/32

  Cardiovascular disorders · CPC title

• C12N2770/36121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title